Application of immune checkpoint inhibitors in the treatment of small cell lung cancer

Abstract

Cao Chun, He Wenqi, Yan Jun. Application of immune checkpoint inhibitors in the treatment of small cell lung cancer[J]. Journal of International Oncology, 2021, 48(12): 747-750.

References21

[1]	Oronsky B, Reid TR, Oronsky A, et al. What's new in SCLC? A review[J]. Neoplasia, 2017,19(10):842-847. DOI: 10.1016/j.neo.2017.07.007.
[2]	Qin H F, Wang F, Liu H, et al. New advances in immunotherapy for non-small cell lung cancer[J]. Am J Transl Res, 2018,10(8):2234-2245.
[3]	Li Y, Li F, Jiang F, et al. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints[J]. Int J Mol Sci, 2016,17(7):1151. DOI: 10.3390/ijms17071151.
[4]	Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC)[J]. Pharmacol Ther, 2017,180:16-23. DOI: 10.1016/j.pharmthera.2017.06.002.
[5]	Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. New Engl J Med, 2012,366(26):2455-2465. DOI: 10.1056/NEJMoa1200694.
[6]	Wieder T, Eigentler T, Brenner E, et al. Immune checkpoint blockade therapy[J]. J Allergy Clin Immunol, 2018,142(5):1403-1414. DOI: 10.1016/j.jaci.2018.02.042.
[7]	Reck M, Heigener D, Reinmuth N. Immunotherapy for small-cell lung cancer: emerging evidence[J]. Future Oncol, 2016: 12(7):931-943. DOI: 10.2217/fon-2015-0012.
[8]	Horn L, Mansfeld AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018,379(23):2220-2229. DOI: 10.1056/NEJMoa1809064.
[9]	Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase ⅢKEYNOTE-604 study[J]. J Clin Oncol, 2020,38(21):2369-2379. DOI: 10.1200/JCO.20.00793.
[10]	Leal T, Wang Y, Dowlati A, et al. Randomized phase Ⅱ clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161[J]. J Clin Oncol, 2020,38(suppl_15):9000. DOI: 10.1200/JCO.2020.38.15_suppl.9000.
[11]	Reck M, Luft A, Szczesna A, et al. Phase Ⅲ randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinm in extensive-stage small-cell lung cancer[J]. J Clin Oncol, 2016,34(31):3740-3748. DOI: 10.1200/JCO.2016.67.6601.
[12]	Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinu-metoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019,394(10212):1929-1939. DOI: 10.1016/s0140-6736(19)32222-6.
[13]	O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase Ⅲ trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer[J]. J Clin Oncol, 2006,24(34):5441-5447. DOI: 10.1200/JCO.2006.06.5821.
[14]	Reck M, Vicente D, Ciuleanu T, et al. Efficacy and safety of ni-volumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331[J]. Ann Oncol, 2018,29(10_Suppl):43. DOI: 10.1093/annonc/mdy511.004.
[15]	Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab inrecurrent small-cell lungcancer (CheckMate032): a multicentre, open-label, phase 1/2 trial[J]. Lancet Oncol, 2016,17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5.
[16]	Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive stage small cell lung cancer: results from the phase Ⅰb KEY-NOTE028 study[J]. J Clin Oncol, 2017,35(34):3823-3829. DOI: 10.1200/JCO.2017.72.5069.
[17]	Chung HC, Lopez-Martin JA, Kao SCH, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158[J]. J Clin Oncol, 2018,36(Suppl_15):8506. DOI: 10.1200/JCO.2018.36.15_suppl.8506.
[18]	Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase Ⅱ study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC)[J]. J Thorac Oncol. 2018,13(9):1393-1399 DOI: 10.1016/j.jtho.2018.05.002.
[19]	Riaz SP, Lüchtenborg M, Coupland VH, et al. Trends in incidence of small cell lung cancer and all lung cancer[J]. Lung Cancer, 2012,75(3):280-284. DOI: 10.1016/j.lungcan.2011.08.004.
[20]	Owonikoko TK, Kim HR, Govindan R, et al. Nivolumab (nivo) plus ipilimumab(ipi), nivo, or placebo(pbo) as maintenance therapy in patients(pts) with extensive disease small cell lung can-cer(ED-SCLC) after first-line(1L) platinum-based chemotherapy(chemo): results from the double-blind, randomized phase Ⅲ CheckMate 451 study[J]. Ann Oncol, 2019, 30(Suppl_2): ii77-ii80. DOI: 10.1093/annonc/mdz094.
[21]	Peters S, Pujol JL, Dafni U, et al. Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: results from the ETOP/IFCT4-12 STIMULI trial[J]. Ann Oncol, 2020,31(S4):S1211. DOI: 10.1016/j.annonc.2020.08.2326.

Application of immune checkpoint inhibitors in the treatment of small cell lung cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References21

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[3]	Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165.
[4]	Chen Xinyi, Weng Yiming, Wei Jiayan, Wang Jinsong, Peng Min.Advances in immune checkpoint inhibitors in the treatment of recurrent or metastatic head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 553-557.
[5]	Deng Juanjun, Zhao Dayong, Li Miao.Adverse reactions and risk factors of immune checkpoint inhibitors in the treatment of non-small cell lung cancer[J]. Journal of International Oncology, 2023, 50(9): 564-568.
[6]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying.Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2023, 50(8): 475-483.
[7]	Guo Ciliang, Jiang Chunping, Wu Junhua.Gut microbiome and tumor immunotherapy[J]. Journal of International Oncology, 2023, 50(7): 432-436.
[8]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong.Progress of PARP inhibitors in targeted therapy of small cell lung cancer[J]. Journal of International Oncology, 2023, 50(6): 368-372.
[9]	Gu Anqin, Long Jinhua, Jin Feng.Clinical research progress of immunotherapy for nasopharyngeal carcinoma[J]. Journal of International Oncology, 2023, 50(5): 299-303.
[10]	Wang Yaqian, Du Yiwei, Wang Xing, Jia Junmei.Prognostic predictors of immunotherapy in patients with small cell lung cancer[J]. Journal of International Oncology, 2023, 50(3): 179-182.
[11]	Huang Rui, Zhang Yunqing.Clinical efficacy of anlotinib monotherapy in second-line treatment of extensive stage small cell lung cancer with poor PS score[J]. Journal of International Oncology, 2023, 50(12): 705-710.
[12]	Jiao Panpan, Xue Lijuan, Zhan Juan.Risk factors and predictors of immune-related adverse events induced by immune checkpoint inhibitors[J]. Journal of International Oncology, 2023, 50(12): 739-744.
[13]	Liu Shaoping, Luo Hanchuan, Lin Shuhan, Luo Jiahui.Current status and research progress of interventional and systemic therapy for advanced hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(12): 758-762.
[14]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu.Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer[J]. Journal of International Oncology, 2023, 50(11): 683-687.
[15]	Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635.